<?xml version="1.0" encoding="utf-8"?>
<Document>
  <Do_id>16173832</Do_id>
  <Journal>PLoS medicine</Journal>
  <Doc_title>Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R.</Doc_title>
  <Doc_abstract>None</Doc_abstract>
  <Doc_ChemicalList>Protein Kinase Inhibitors;Quinazolines;Receptor, Epidermal Growth Factor;gefitinib</Doc_ChemicalList>
  <Doc_meshdescriptors>Adenocarcinoma;Drug Administration Schedule;Drug Resistance, Neoplasm;Female;Humans;Lung Neoplasms;Middle Aged;Mutation;Protein Kinase Inhibitors;Quinazolines;Receptor, Epidermal Growth Factor</Doc_meshdescriptors>
  <Doc_meshqualifiers>drug therapy;genetics;genetics;drug therapy;genetics;administration &amp; dosage;therapeutic use;administration &amp; dosage;therapeutic use;antagonists &amp; inhibitors;genetics</Doc_meshqualifiers>
</Document>
